a year ago

Theolytics Secures £19 Million to Advance Oncolytic Viral Therapy into Clinical Trials

  • Theolytics, a UK-based biotechnology company developing oncolytic viral therapies, has raised £19 million in funding

  • The investment will be used to advance the company's lead oncolytic adenovirus, THEO-260, into clinical trials in ovarian cancer

  • Theolytics is working to develop oncolytic viral therapies suitable for systemic intravenous delivery

  • THEO-260 is a next-generation oncolytic adenovirus for the treatment of (platinum-resistant) ovarian cancer

  • It is highly efficacious in killing cancer cells and cancer-associated fibroblasts in ovarian cancer patient tumor samples.

      • ProblemHealthcare

      "Current treatment options for ovarian cancer are limited, with many patients experiencing platinum resistance."

      Solution

      "Theolytics is developing oncolytic viral therapies, like THEO-260, that can target and kill cancer cells, including platinum-resistant ovarian cancer cells and cancer-associated fibroblasts, which can hinder the effectiveness of other treatments."

      Covered on